Chicken HSP70 DNA vaccine inhibits tumor growth in a canine cancer model.

Abstract

Immunization with xenogeneic DNA is a promising cancer treatment to overcome tolerance to self-antigens. Heat shock protein 70 (HSP70) is over-expressed in various kinds of tumors and is believed to be involved in tumor progression. This study tested a xenogeneic chicken HSP70 (chHSP70) DNA vaccine in an experimental canine transmissible venereal tumor (CTVT) model. Three vaccination strategies were compared: the first (PE) was designed to evaluate the prophylactic efficacy of chHSP70 DNA vaccination by delivering the vaccine before tumor inoculation in a prime boost setting, the second (T) was designed to evaluate the therapeutic efficacy of the same prime boost vaccine by vaccinating the dogs after tumor inoculation; the third (PT) was similar to the first strategy (PE), with the exception that the electroporation booster injection was replaced with a transdermal needle-free injection. Tumor growth was notably inhibited only in the PE dogs, in which the vaccination program triggered tumor regression significantly sooner than in control dogs (NT). The CD4(+) subpopulation of tumor-infiltrating lymphocytes and canine HSP70 (caHSP70)-specific IFN-γ-secreting lymphocytes were significantly increased during tumor regression in the PE dogs as compared to control dogs, demonstrating that specific tolerance to caHSP70 has been overcome. In contrast, no benefit of the therapeutic strategy (T) could be noticed and the (PT) strategy only led to partial control of tumor growth. In summary, antitumor prophylactic activity was demonstrated using the chHSP70 DNA vaccine including a boost via electroporation. Our data stressed the importance of DNA electroporation as a booster to get the full benefit of DNA vaccination but also of cancer immunotherapy initiation as early as possible. Xenogeneic chHSP70 DNA vaccination including an electroporation boost is a potential vaccine to HSP70-expressing tumors, although further research is still required to better understand true clinical potential.

• Authors: Wen-Ying Yu, Tien-Fu Chuang, Cécile Guichard, Hanane El-Garch, Dominique Tierny, Albert Taiching Laio, Ching-Si Lin, Kuo-Hao Chiou, Cheng-Long Tsai, Chen-Hsuan Liu, Wen-Chiuan Li, Laurent Fischer, Rea-Min Chu
• Journal: Vaccine (Vaccine) Vol. 29 Issue 18 Pg. 3489-500 (Apr 18 2011) ISSN: 1873-2518 [Electronic] Netherlands
• PMID: 21392590 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2011 Elsevier Ltd. All rights reserved.

Chemical References

• Cancer Vaccines
• HSP70 Heat-Shock Proteins
• Vaccines, DNA
• Interferon-gamma

Topics

• Amino Acid Sequence
• Animals
• CD4-Positive T-Lymphocytes (immunology)
• CD8-Positive T-Lymphocytes (immunology)
• Cancer Vaccines (immunology)
• Chickens
• Dogs
• Electroporation
• HSP70 Heat-Shock Proteins (immunology)
• Interferon-gamma (immunology)
• Killer Cells, Natural (immunology)
• Molecular Sequence Data
• Sequence Alignment
• Vaccination
• Vaccines, DNA (immunology)
• Venereal Tumors, Veterinary (immunology, prevention & control)